Is Innoviva Inc (INVA) overvalued? · P/E 3.6, rev $358.7M
Innoviva Inc (INVA) is a biotechnology company listed on US.
This page asks whether Innoviva Inc (INVA) looks expensive on cached numbers — not a short thesis.
Latest reported INVA revenue for 2024-12-31 was $358.7M. Net income was $23.4M. Revenue was up 15.5% from 2023-12-31 to 2024-12-31. INVA currently screens at market cap $1.66B and trailing P/E 3.6.
INVA currently screens at market cap $1.66B and trailing P/E 3.6. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next INVA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the INVA stock page for the full model, not this heading.
Not investment advice.